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Introduction
Duchenne muscular dystrophy (DMD) is a fatal neuromuscular disease that occurs in one in 3500 male births (Emery, 1991) . Patients have defects in the dystrophin gene, which results in a lack of the structural protein dystrophin (427 kDa). Dystrophin is a rod-shaped protein expressed in skeletal, cardiac and smooth muscle, where it links cytoskeletal actin to the sarcolemma and has a physiological role in preventing damage during muscle contraction (Nowak & Davies, 2004) . The absence of dystrophin in DMD induces severe damage to muscle fibres, with resultant inflammation (Deconinck & Dan, 2007) . As the disease progresses there is a loss of functional muscle fibres because of necrosis, and the deposition of fibrotic and adipose tissue prevails, resulting in muscle weakness.
The respiratory system is severely impaired in DMD because of respiratory and abdominal muscle weakness, as well as scoliosis (De Bruin et al. 1997; Beck et al. 2006) . Duchenne muscular dystrophy is a progressive disease, and thus, respiratory function deteriorates with age, with patients often presenting with reduced vital capacity and breathing disturbances, such as hypoventilation and sleep-disordered breathing (Smith et al. 1989; Hill et al. 1992; Barbé et al. 1994) . Although the diaphragm has been the focus of many studies in this field, there is a paucity of information pertaining to the upper airway muscles controlling airway calibre and collapsibility, thereby facilitating breathing (White & Younes, 2012) . The prevalence of obstructive sleep apnoea in DMD (Suresh et al. 2005) suggests that upper airway muscle dysfunction and poor control of airway patency during sleep potentially contribute to breathing disturbances in DMD.
The mdx mouse is the most widely studied animal model of DMD. We have previously reported respiratory dysfunction, which presents at an early age in the mdx mouse (8 weeks), consisting of hypoventilation and upper airway (sternohyoid) muscle weakness (Burns et al. 2015; Burns & O'Halloran, 2016) . In human patients and mdx mice, functional impairments are driven by pathological changes in skeletal muscles attributable to dystrophin deficiency, including fibre degeneration and necrosis, with inflammation thought to play an integral part in DMD muscle pathology (Deconinck & Dan, 2007) .
In patients and mdx mice, sarcolemmal damage is accompanied by the infiltration of immune cells, primarily macrophages and T cells, a key source of inflammatory cytokines (Moran & Mastaglia, 2014) . These molecules mount an inflammatory response through activation of additional cytokines and recruitment of further immune cells to the damaged muscle (Villalta et al. 2015) . Immune cells are not the only source of cytokines, with damaged muscles fibres also serving as a contributory factor (Whitham & Febbraio, 2016) . In DMD, the heightened expression of pro-inflammatory cytokines, such as tumour necrosis factor-α, interleukin-1 (IL-1) and interleukin-6 (IL-6), are early disease indicators and are associated with exacerbation of the inflammatory response in dystrophic muscle (Evans et al. 2009a,b) . Interleukin-6 is released from a variety of tissues, including immune cells and adipocytes, and is commonly referred to as a myokine because it can be secreted from muscle in response to physical activity (Jonsdottir et al. 2000; Pedersen & Febbraio, 2008) . This inflammatory cytokine is of particular interest in DMD pathology because it is elevated in muscle and plasma samples from DMD patients (Messina et al. 2011; Rufo et al. 2011; Pelosi et al. 2015a) and mdx mice (Pelosi et al. 2015a ). Ineterleukin-6 is pleiotropic, but it mediates its pro-inflammatory effects via its trans-signalling pathway by use of the soluble IL-6 receptor (IL-6R; Pedersen & Febbraio, 2008) . Its importance in mdx skeletal muscle pathology was recently highlighted (Pelosi et al. 2015a) , showing that blockade of IL-6 signalling in mdx mice has beneficial functional outcomes in dystrophic skeletal muscle.
Muscle wasting is a common feature of DMD, resulting from muscle proteolysis; thus, pharmacological interventions aimed at rescuing muscle are attractive. Corticotrophin-releasing factor receptor 2 (CRFR2) agonists have been shown to modulate muscle mass through the activation of anabolic signalling pathways and a capacity to alter the rate of proteolysis during atrophying conditions (Hall et al. 2007 ). In addition, CRFR2 can reduce nerve damage, corticosteroid-induced atrophy and loss of muscle mass attributable to immobilization (Hinkle et al. 2003) . The CRFR2 agonist, urocortin 2 (Ucn2), Factors contributing to pharyngeal dilator weakness in mdx mice has been shown to improve diaphragm function and reduce fibrosis and immune cell infiltration in mdx mice (Reutenauer-Patte et al. 2012) . Recent work demonstrated that neutralization of the IL-6 receptor (xIL-6R) or stimulation of CRFR2 both had positive inotropic effects on the major pump muscle of breathing, the diaphragm (Manning et al. 2017) . Furthermore, Manning et al. (2017) reported that co-treatment of xIL-6R and Ucn2 had an additive inotropic effect on diaphragm muscle force. We hypothesized that co-administration of xIL-6R antibodies and Ucn2 alleviates upper airway muscle weakness in dystrophin-deficient mdx mice. We sought to examine the structure and function of sternohyoid muscle (pharyngeal dilator) from age-matched wild-type (WT) and mdx mice following saline or combined xIL-6R and Ucn2 drug treatment.
Methods

Ethical approval
All procedures were performed under licence in accordance with national and European guidelines following local research ethics committee approval (approval no. AEEC 2013/035).
Animals
Male and female wild-type (WT; C57BL/10ScSnJ) and mdx (C57BL/10ScSn-Dmd mdx /J) mice were purchased from the Jackson Laboratory (Jackson Laboratory, Bar Harbor, ME, USA) and were bred in our institution's animal housing facility. Animals were housed conventionally in a temperature-and humidity-controlled facility, operating on a 12 h light-12 h dark cycle with food and water available ad libitum. Six-week-old male WT and mdx mice received a treatment consisting of a co-administration of xIL-6R [IL-6R neutralizing antibody; MR1-61 (Okazaki et al. 2002) ; 0.2 mg kg −1 ] and Ucn2 (CRFR2 agonist; 30 μg kg −1 ; U9507; Sigma Aldrich, Wicklow, Ireland) or saline (vehicle control; 0.9% w/v). MR1-61 stock was kept at −80°C and Ucn2 stock at −20°C. A working solution containing both MR1-61 (26.7 μg ml −1 ) and Ucn2 (4 μg ml −1 ) was made in sterile saline, aliquoted and stored at −20°C until the day of injection. The doses and treatment protocol were chosen based on previous studies (Manning et al. 2016 (Manning et al. , 2017 . Treatment consisted of six S.C. injections to the scruff of the neck on alternate days over the course of 2 weeks beginning at 6 weeks of age. A 20 g mouse received an injection bolus of 150 μl. The WT and mdx animals were assigned at random to saline or drug treatment, establishing the following four groups: WT saline (21.4 ± 1.6 g; n = 13); WT treatment (22.0 ± 1.2 g; n = 13); mdx saline (24.4 ± 1.6 g; n = 13); and mdx treatment (24.5 ± 1.7 g; n = 13). Animals were anaesthetized with 5% isoflurane by inhalation in oxygen and killed by cervical dislocation.
Muscle physiology
Ex vivo muscle preparation. The sternohyoid muscles were immediately excised and placed in a tissue bath at room temperature containing continuously gassed hyperoxic (95% O 2 -5% CO 2 ) Krebs solution (mM: NaCl, 120; KCl, 5; calcium gluconate, 2.5; MgSO 4 , 1.2; NaH 2 PO 4 , 1.2; NaHCO 3 , 25; and glucose, 11.5) and d-tubocurarine (25 μM). The paired sternohyoid muscles were carefully separated along a natural division in the mid-line. One half was used immediately for functional analysis and the other half was snap frozen in liquid nitrogen for subsequent molecular analysis.
A single longitudinal muscle strip (2 mm in diameter) for each animal was studied in a water-jacketed muscle bath, containing Krebs solution, maintained at 35°C and gassed with 95% O 2 -5% CO 2 . Each muscle strip was placed between a pair of platinum plate electrodes, with the caudal end fixed to an immobile hook and the rostral end attached to a dual-mode lever transducer system by non-elastic string. Muscle preparations were allowed a 5 min equilibration period.
Isometric protocol. Following equilibration, the optimal length (L o ) was determined by adjusting the position of the force transducer by use of a micro-positioner between intermittent twitch contractions. The L o was taken as the muscle length associated with maximal isometric twitch force in response to single isometric twitch stimulation (supramaximal stimulation, 1 ms duration). Once L o was determined, the muscle stayed at this length for the duration of the protocol. A single isometric twitch was measured. Peak isometric twitch force, contraction time (CT; time to peak force) and half relaxation time (½RT; time for peak force to decay by 50%) were determined. Next, an isometric tetanic contraction was elicited by stimulating muscle strips with supramaximal voltage at 100 Hz for 300 ms duration. Peak isometric tetanic force was determined at 100 Hz (O'Halloran, 2006; Burns & O'Halloran, 2016) .
Isotonic protocol. After the isometric protocol, concentric contractions were elicited in incremental steps with varying load (0, 5, 10, 15, 20, 25, 30, 35, 40 and 60% of force at 100 Hz), with 30 s rest between each contraction. Muscle length returned to L o after each contraction. Total shortening was determined as the maximal distance shortened during contraction. Shortening velocity was determined as the distance shortened during the initial 30 ms of shortening (Lewis et al. , 2016 . Mechanical work (force × total shortening) and power (force × shortening velocity) D. P. Burns and others were determined at each step of the incremental load step test Williams et al. 2015; Burns & O'Halloran, 2016; O'Leary & O'Halloran, 2016) .
Muscle immunohistochemistry and histology
Tissue preparation. The sternohyoid muscles were excised and divided down the mid-line; one half was embedded in optimum cutting temperature (OCT) embedding medium, frozen in isopentane cooled in liquid nitrogen and stored at −80°C for subsequent structural analysis (n = 4-5 per group). The other half of the muscle was placed in 4% paraformaldehyde overnight at 4°C before being transferred to 70% ethanol prior to tissue processing and paraffin embedding for histological analysis (n = 4-5 per group).
Myosin heavy chain fluorescence immunohistochemistry.
Serial transverse muscle sections (10 μm thick) were cryo-sectioned (model CM30505; Leica Microsystems, Nussloch, Germany) at -22°C and mounted on polylysine-coated glass slides (VWR International, Dublin, Ireland). Sections were captured from the middle belly and distal regions of the muscle. Slides were immersed in PBS (0.01 M) containing 1% bovine serum albumin for 15 min. After three 5 min PBS washes, slides were immersed in PBS containing 5% goat serum for 30 min. After a further three 5 min PBS rinses, slides were incubated with an unconjugated AffiniPure Fab Fragment Goat Anti-Mouse IgG (H+L) diluted in PBS (1:13; Jackson ImmunoResearch Europe Ltd., Suffolk, UK) for 1 h at room temperature, to enable the use of mouse monoclonal primary antibody staining on mouse tissue. After three 2 min washes in PBS, primary antibodies were applied. Primary monoclonal myosin antibodies were obtained from the Developmental Studies Hybridoma Bank (DSHB), University of Iowa, Iowa City, IA, USA and a rabbit anti-laminin antibody was obtained from Sigma Aldrich (L9393). A triple-labelling approach was applied to tag myosin heavy chain (MHC) types I (BAD5, 1:100), IIa (sc71 1:100) and IIb (BFF3, 1:100) on a single section. On a serial section, a double-labelling approach consisted of a rabbit anti-laminin antibody (1:500) and a pan-MHC antibody for the indirect determination of pure MHC IIx fibres, BF35 (1:50), labelling all MHC isoforms but IIx, enabling visualization of IIx fibres by absence of staining; all antibodies were diluted in PBS and 1% bovine serum albumin solution. Triple-and double-labelling solutions were applied on alternate sections on each slide. Individual sections were encircled with a hydrophobic pen (ImmEdge TM ; Vector Laboratories Ltd., Peterborough, UK) to prevent contamination from neighbouring sections on the same slide. Slides were incubated with the primary antibodies overnight at 4°C in a humidified chamber.
After the incubation period, slides were washed three times with PBS, each for 5 min, before the appropriate secondary antibodies were applied. All secondary antibodies were diluted in PBS and 1% bovine serum albumin. For the triple-labelled slides, a cocktail of secondary antibodies was prepared containing Alexa Fluor 350-conjugated goat anti-mouse IgG2b (1:500; Invitrogen, Biosciences Ltd, Dun Laoghaire, Ireland), Dylight 594-conjugated goat anti-mouse IgG1 (1:500; Jackson ImmunoResearch Europe Ltd, Newmarket, UK) and Alexa Fluor 488-conjugated goat anti-mouse IgM (1:250; Invitrogen), targeting MHC I, IIa and IIb, respectively. Secondary antibodies for double-labelled sections were Dylight 594-conjugated goat anti-mouse IgG1 (1:500; Jackson ImmunoResearch Europe Ltd) and FITC-conjugated anti-rabbit secondary antibody (1:250; Sigma Aldrich). Secondary antibodies were applied, and slides were incubated for 1 h in the dark at room temperature. Slides were rinsed three times with PBS, each for 5 min, and coverslipped with polyvinyl alcohol mounting medium with DABCO R anti-fade (Sigma) before observation with a fluorescent microscope (Olympus BX51). Negative controls were also performed, in which primary antibodies were omitted and sections were instead incubated in diluent. Images were merged using ImageJ software (W. S. Rasband, ImageJ; US National Institutes of Health, Bethesda, MD, USA).
Histological analysis. Muscle samples were dehydrated (70, 80 and 95% ethanol, 60 min each) and then placed in 100% ethanol (two times, each for 60 min). Samples were then cleared in xylene (two times, each for 60 min), before being transferred to two changes of paraffin (1 h each; Leica TP1020; Histokinet, Leica Biosystems, Dublin, Ireland). Tissue samples were then embedded in paraffin (Sakura Tissue-Tek TEC, Histolab Histowax embedding medium), and serial cross-sections (5 μm thick) were sectioned using a microtome (Leica RM2135). Serial sections were collected throughout the muscle (mid-belly and distal regions) onto glass slides and oven dried (overnight at 37°C).
To examine putative inflammatory cell infiltration and central nucleation of muscle fibres, tissue sections were stained with Haematoxylin and Eosin (H&E). Tissue sections were deparaffinized in xylene (two times, each for 5 min), rehydrated through a graded series of alcohols (100, 95 and 70% ethanol, 1 min each). Sections were stained with Haematoxylin (Delafield's Haematoxylin; for 5 min) and subsequently rinsed in distilled H 2 O (5 min), stained in Eosin (alcoholic Eosin-Y; Sigma Aldrich; for 1 min), rinsed in distilled H 2 O, and dehydrated (70 and 95% ethanol, 1 min each, and 100% ethanol, two times 1 min) and xylene (5 min). For collagen staining, a Masson's trichrome protocol was followed (Sigma Aldrich). Slides were mounted using DPX mounting medium (Sigma Factors contributing to pharyngeal dilator weakness in mdx mice Aldrich, USA), air dried and viewed on a bright-field microscope (Olympus BX51) at ×20 magnification.
Molecular studies
Tissue preparation. Sternohyoid samples stored at −80°C were removed and allowed to defrost at 4°C for 5 min. All procedures were performed at 4°C to prevent protein degradation. Samples were homogenized in a lysis buffer (RIPA) made up from 10× RIPA, deionized water, 200 mM sodium fluoride, 100 mM phenylmethylsulfonylfluoride (PMSF), protease cocktail inhibitor 1 and phosphatase cocktail inhibitor 2. After the homogenization process, the reactant mixtures were centrifuged (13,000 g) at 4°C for 20 min and the supernatants harvested. The total amount of protein for each tissue sample was determined using the Pierce bicinchoninic acid assay (BCA assay; Thermo Fisher Scientific, Dublin, Ireland). Supernatants were stored at −80°C for future use.
Chemokines. A chemokine assay (U-PLEX Chemokine Combo, K15099K-1; Meso Scale Discovery, Rockville, MD, USA) was used to examine chemokines in sternohyoid muscle from all four groups: WT saline (n = 7-8), WT treatment (n = 7-8), mdx saline (n = 8) and mdx treatment (n = 7). The assay was performed according to the manufacturer's instructions, using an extended incubation time to improve detection (the plate was incubated overnight at 4°C). Following incubation, the plate was read on a QuickPlex SQ 120 imager (Meso Scale Discovery). Signals within the detectable range were achieved with reliability for the following three chemokines: macrophage inflammatory protein 2 (MIP-2), interferon-γ-induced protein 10 (IP-10) and macrophage inflammatory protein 3α (MIP-3α).
Data and image analysis
Specific force was calculated in newtons per centimetre squared of estimated muscle cross-sectional area (CSA). The CSA of each strip was determined by dividing the muscle mass (weight in grams) by the product of muscle L o (in centimetres) and muscle density (assumed to be 1.06 g cm −3 ). The CT and ½RT were measured as indices of isometric twitch kinetics. For isotonic load relationships, data were plotted as the measured variable versus percentage load. Total muscle shortening was normalized to L o and expressed as L/L o . Likewise, shortening velocity was normalized to L o and expressed as L o per second. Maximal total shortening (S max ) and maximal shortening velocity (V max ) were measured when both were maximal at 0% load. Mechanical work was measured in joules per centimetre squared. Mechanical power was expressed in watts per centimetre squared. Maximal mechanical work (W max ) and power (P max ) were also measured and typically occurred between 30 and 40% load.
For MHC fibre-type analysis, muscle sections were viewed at ×10 magnification and images captured using an Olympus BX51 microscope and an Olympus DP71 camera. Cell Sens TM (Olympus) was used to capture the images digitally. Analysis was carried out using ImageJ software, where fibre-type CSA and fibre-type distribution for each MHC fibre type were determined. Measurements of CSA were made by fibre 'circling' based on MHC labelling. A square test frame (640,000 μm 2 ) with inclusion and exclusion boundaries was used to calculate these parameters in a given randomly chosen field. For each animal, multiple sections throughout the length of the muscle were viewed and three or four images analysed per fibre type. Haematoxylin-and Eosin-stained sections were viewed at ×20 magnification. Six sections were examined across the muscle from the rostral, middle and caudal regions. Two randomly selected areas were captured per muscle section from non-overlapping areas for analysis. Muscle pathology was scored using ImageJ software. The number of myofibres displaying central nucleation was expressed as a percentage of the total number of myofibres per image. Putative inflammatory cell infiltration (the presence of cells in the extracellular matrix), was also scored and expressed as a percentage of the total area of muscle. For Masson's trichrome staining, the microscope lighting exposure was maintained throughout. Three sections, with two images captured per section, from the mid-portion of the muscle, were analysed per animal. Images were analysed using a colour balance threshold (ImageJ software), and the area of collagen was expressed as a percentage of the total area of muscle. For chemokine analysis, chemokine signals within the detectable range were expressed as relative fluorescence units per microgram of protein [RFU (μg protein)
−1 ], with equal protein loading in all wells.
Statistical analysis
Values are expressed as means ± SD. Muscle functional data were statistically compared using two-way ANOVA (genotype × treatment) with the Bonferroni post hoc test. For muscle histology, group means were generated from multiple images averaged per animal and then compared by two-way ANOVA (genotype × treatment) with the Bonferroni post hoc test. A value of P < 0.05 was deemed to be statistically significant.
Results
Body mass
There was a significant difference in body mass (P < 0.0001; two-way ANOVA) between age-matched D. P. Burns and others 4 . 7± 1.7 7.4 ± 3.9 2.1 ± 1.5 * 3.6 ± 0.6 0.0003 0.01
Values (means ± SD) for twitch contraction time (CT), twitch half-relaxation time (½RT), peak twitch force, maximal mechanical work (W max ), maximal mechanical power (P max ), peak shortening (S max ) and peak shortening velocity (V max ) of sternohyoid muscle from wild-type (WT; n = 7-8) and mdx (n = 7-8) mice injected S.C. with saline (0.9% w/v) or drug treatment [neutralizing interleukin-6 receptor antibodies (0.2 mg kg −1 ) and urocortin 2 (30 μg kg −1 ); co-administered] for 2 weeks. Data were statistically compared by two-way ANOVA followed by Bonferroni post hoc test. * mdx saline significantly different from corresponding WT saline value, P < 0.05. † WT treatment significantly different from corresponding WT saline value, P < 0.05. ‡ mdx treatment significantly different from corresponding mdx saline value, P < 0.05.
WT and mdx mice; the latter were slightly heavier. Drug treatment had no effect on body mass. Table 1 shows data for sternohyoid muscle twitch force and contractile kinetics (CT and ½RT) from animals following drug or saline treatment. Mdx sternohyoid twitch force was significantly lower [P = 0.01 (genotype); two-way ANOVA] compared with WT. Post hoc analysis revealed that drug treatment significantly increased twitch force in mdx sternohyoid (P < 0.01; two-way ANOVA with Bonferroni post hoc test), but not in WT (P > 0.05). There was no significant difference between WT and mdx in values for CT and ½RT; both were unaffected by drug treatment. Although statistical differences were not observed for CT and ½RT across groups, sizeable effects were noticed, which could have physiological relevance. Contraction time was increased by ß45% and ½RT by ß28% for mdx sternohyoid compared with WT. Treatment reduced CT by ß18% and ½RT by ß19% in mdx mice. Peak force at 100 Hz was significantly lower in mdx sternohyoid (P = 0.0003) compared with WT ( Fig. 1) . Post hoc analysis showed that drug treatment significantly increased force for WT (P < 0.01) and mdx (P < 0.01) sternohyoid.
Isometric force and twitch contractile kinetics
Isotonic contractile parameters and kinetics Table 1 shows data for sternohyoid muscle isotonic contractile parameters: W max , P max , S max and V max . The W max was significantly reduced in mdx sternohyoid (P = 0.004; two-way ANOVA) compared with WT. Drug treatment significantly increased W max for WT (P < 0.05; two-way ANOVA with Bonferroni post hoc test), but not mdx muscle (P > 0.05). The P max was significantly reduced in mdx sternohyoid (P = 0.0003) compared with WT, and drug treatment significantly increased P max in mdx (P = 0.01). The V max was significantly reduced in mdx sternohyoid (P = 0.008) compared with WT, and this was unaffected by drug treatment. There was no significant difference in S max between WT and mdx. Drug treatment had no effect on S max in both groups.
Isotonic load relationships
Figure 2 shows data for sternohyoid muscle isotonic load relationships. Loading had a significant effect on work (P < 0.0001; two-way ANOVA; Fig. 2A 
Peak isometric tetanic force
Group data (means ± SD) for tetanic force in wild-type (WT; n = 7-8) and mdx (n = 7-8) sternohyoid muscle after six S.C. injections with saline (0.9% w/v) or treatment [xIL-6R (0.2 mg kg −1 ) and Ucn2 (30 μg kg −1 ); co-administered] over 2 weeks. Peak tetanic force was measured following stimulation at 100 Hz ex vivo. Data were statistically compared by two-way ANOVA followed by Bonferroni post hoc test. Genotype, P = 0.0003; treatment, P = 0.0001; and interaction, P = 0.9. * * P < 0.01. * * * P < 0.001 compared with WT.
(P < 0.0001; Fig. 2B ), shortening (P < 0.0001; Fig. 2C ) and shortening velocity (P < 0.0001; Fig. 2D ) for both WT and mdx sternohyoid. Mdx muscle had significantly reduced work (P < 0.0001), power (P < 0.0001) and shortening velocity (P < 0.0001) compared with WT. Drug treatment significantly increased work production for WT (P < 0.0001; two-way ANOVA with Bonferroni post hoc test) and mdx muscle (P < 0.0001). Power production was also significantly increased for WT (P < 0.0001) and mdx (P < 0.0001) sternohyoid after drug treatment. Shortening velocity was significantly increased for mdx muscle (P = 0.02) after drug treatment.
Myosin heavy chain fibre-type distribution
Type I fibres were absent from sternohyoid muscle in all groups. A positive control image for type I fibre staining in WT mouse diaphragm muscle is shown in Fig. 3A . The fibre-type distribution of type IIa fibres did not vary significantly between the four groups (Fig. 3B) . For mdx saline, the distribution of type IIx fibres was significantly increased compared with WT saline ( Fig. 3C ; P < 0.0001; two-way ANOVA), whereas the distribution of type IIb fibres was significantly reduced in mdx saline compared with WT saline ( Fig. 3D ; P < 0.01). Sternohyoid fibre-type changes were prevented or reversed by drug treatment in mdx, with significant changes in type IIx ( Fig. 3C ; P < 0.01; two-way ANOVA with Bonferroni post hoc test) and type IIb fibres ( Fig. 3D ; P < 0.05) compared with mdx saline.
Fibre cross-sectional area Figure 3E shows data for the CSA for all fibre types. There was a significant increase in the CSA of type IIa (P < 0.05; two-way ANOVA) and type IIx fibres (P < 0.05) in mdx sternohyoid compared with WT. Drug treatment had no significant effect on type IIa (P = 0.08) or type IIx (P = 0.628) CSA for both WT and mdx. The CSA of and urocortin 2 (30 μg kg −1 ); co-administered] over 2 weeks. Data were statistically compared by twoway ANOVA. Work: load, P < 0.0001; genotype, P < 0.0001; WT treatment, P < 0.0001; and mdx treatment, P < 0.0001. Power: load, P < 0.0001; genotype, P < 0.0001; WT treatment, P < 0.0001; and mdx treatment, P < 0.0001. Shortening: load, P < 0.0001; genotype, P = 0.2; WT treatment, P = 0.5; and mdx treatment, P = 0.2. Velocity: load, P < 0.0001; genotype, P < 0.0001; WT treatment, P = 0.2; and mdx treatment, P = 0.002.
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type IIb fibres were not significantly different between WT and mdx. With treatment, type IIb CSA was significantly increased in WT only (P < 0.05; two-way ANOVA with Bonferroni post hoc test).
Central nucleation and putative inflammatory cell infiltration
The percentage of sternohyoid muscle fibres with centrally located nuclei was significantly increased in mdx ( 
B-D, group data (means + SD) showing fibre distribution of type IIa (B), type IIx (C) and type IIb fibres (D)
in WT (n = 4) and mdx saline-treated mice (n = 5), and WT drug-treated (n = 4) and mdx drug-treated mice (n = 4). Mice received six S.C. injections of saline (0.9% w/v) or treatment [neutralizing interleukin-6 receptor antibodies (0.2 mg kg −1 ) and urocortin 2 (30 μg kg −1 ); co-administered] over 2 weeks. Data were statistically compared by two-way ANOVA followed by Bonferroni post hoc test. In mdx mice, type IIx areal density was significantly increased (C), whereas type IIb fibre distrubution was decreased (D). With drug treatment, type IIx fibre distribution was significantly decreased in mdx mice compared with mdx saline (C), whereas type IIb fibre distribution (D) was increased in comparison to mdx saline. * P < 0.05; * * P < 0.01. B, genotype, P = 0.3; treatment, P = 0.3; and interaction, P = 0.4. C, genotype, P = 0.0001; treatment, P = 0.007; and interaction, P = 0.03. D, genotype, P = 0.006; treatment, P = 0.04; and interaction, P = 0.1. E, group data (means + SD) showing mean CSAs of sternohyoid muscle fibre type IIa, type IIx and type IIb. The CSA of type IIa and type IIx fibres was significantly increased in mdx mice. Drug treatment increased the CSA of type IIb fibres in WT mice only. Type IIa: genotype, * P = 0.03; treatment, P = 0.08; and interaction, P = 0.5. Type IIx: genotype, * P = 0.02; treatment, P = 0.6; and interaction, P = 0.8. Type IIb: genotype, P = 0.3; treatment, * P = 0.049; and interaction, P = 0.1. Factors contributing to pharyngeal dilator weakness in mdx mice and B; P < 0.0001; two-way ANOVA) compared with WT sternohyoid. Central nucleation was reduced slightly in mdx mice following drug treatment compared with mdx saline ( Fig. 4A and B; P < 0.05; two-way ANOVA with Bonferroni post hoc test). The areal density of inflammatory cell infiltration was significantly increased in mdx sternohyoid muscle ( Fig. 4A and C; P < 0.001; two-way ANOVA) compared with WT. Drug treatment had no significant effect on the relative area of putative immune cell infiltration ( Fig. 4A and C) . Peripherally located nuclei are apparent in WT saline and WT drug-treated images. In comparison, mdx mice (saline and drug-treated) displayed an increased incidence of centrally located nuclei. Inflammatory cell infiltration is not apparent in WT saline and WT drug-treated groups. The mdx muscle (saline and treatment) displayed inflammatory cell infiltration, highlighted with black arrows. B and C, group data (means + SD) showing the percentage of central nucleation (B) and percentage of infiltration of inflammatory cells (C) in sternohyoid muscle from saline-treated WT (n = 4-5) and saline-treated mdx mice (n = 5), and WT (n = 4-5) and mdx (n = 4-5) mice treated with neutralizing interleukin-6 receptor antibodies (0.2 mg kg −1 ) and urocortin 2 (30 μg kg −1 ), co-administered as six S.C. injections over 2 weeks. Data were statistically compared by two-way ANOVA followed by Bonferroni post hoc test. The percentage of centrally nucleated fibres was significantly increased in mdx mice. Drug treatment slightly ameliorated central nucleation in mdx mice only. The percentage of inflammatory cell infiltrates was significantly increased in mdx mice. Drug treatment did not affect this response; P = 0.2284 compared with mdx. * P < 0.05. Central nucleation: genotype, P < 0.0001; treatment, P = 0.1; and interaction, P = 0.02. Infiltration: genotype, P = 0.0002; treatment, P = 0.2; interaction, P = 0.2.
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Collagen content
Masson's trichrome staining was applied to investigate muscle collagen content between groups. The percentage area of collagen was significantly increased in mdx sternohyoid compared with WT ( Fig. 5A and B ; P = 0.0103; two-way ANOVA). Drug treatment had no significant effect on collagen content for both WT (P > 0.05) and mdx (P > 0.05) sternohyoid.
Chemokines Figure 6 shows data for chemokine content in sternohyoid muscle from WT and mdx mice after drug or saline treatment. Macrophage inflammatory protein 2, IP-10 and MIP-3α were significantly increased in the mdx sternohyoid (P < 0.0002, MIP-2 and IP-10; P = 0.004, MIP-3α; two-way ANOVA) compared with WT controls. Post hoc analysis revealed that drug treatment significantly showing the percentage of collagen content in sternohyoid muscle from saline-treated WT (n = 5) and saline-treated mdx mice (n = 4), and WT (n = 4) and mdx (n = 5) mice treated with neutralizing interleukin-6 receptor antibodies (0.2 mg kg −1 ) and urocortin 2 (30 μg kg −1 ), co-administered as six S.C. injections over 2 weeks. Data were statistically compared by two-way ANOVA followed by Bonferroni post hoc test. The percentage of collagen content was significantly increased in mdx mice. Drug treatment had no significant effect on collagen content for both WT and mdx. Genotype, P = 0.0103; treatment, P = 0.0673; and interaction, P = 0.7779.
increased MIP-2, IP-10 and MIP-3α in mdx sternohyoid (P < 0.0001, MIP-2 and IP-10; P < 0.01, MIP-3α; two-way ANOVA with Bonferroni post hoc test), but not in WT mice (P > 0.05; Fig. 6A-C) .
Discussion
The key findings of the present study are as follows: (i) sternohyoid muscle weakness in mdx mice is evidenced by reduced specific force and power output; (ii) sternohyoid weakness is associated with changes in myosin heavy chain isoform expression, with an increase in the abundance of type IIx and a concomitant decrease in type IIb fibres; (iii) the incidence of centrally nucleated muscle fibres, percentage and areal density of inflammatory cell infiltrates, and deposition of collagen were significantly increased in mdx sternohyoid; (iv) chemokines were significantly increased in mdx sternohyoid; (v) co-treatment with the xIL-6R antibody and Ucn2 restored mechanical force and power production in mdx sternohyoid muscle; (vi) drug treatment significantly prevented or reversed fibre transitions in mdx sternohyoid and reduced the proportion of centrally nucleated fibres, but did not affect the total area of putative inflammatory cell infiltration or the collagen content within mdx muscle; and (vii) drug treatment significantly increased chemokines in mdx sternohyoid muscle. Chronic respiratory insufficiency is a cardinal feature of DMD. The diaphragm is severely affected, with muscle fibre degeneration and fibrosis being central characteristics of the disease (De Bruin et al. 1997) . Duchenne muscular dystrophy patients often suffer from sleep-disordered breathing, with episodes of hypoventilation during sleep, associated with aberrant blood gas disturbances, necessitating ventilator use at later stages to maintain respiratory function (Hukins & Hillman, 2000) .
The mdx mouse, a dystrophin-deficient model (Bulfield et al. 1984) , has been studied extensively to understand the pathophysiology of DMD and has also served as a preclinical model for the study of pharmacological treatment strategies (Manning & O'Malley, 2015) . As DMD progresses, cardiopulmonary failure is the leading cause of death (Hukins & Hillman, 2000) . The dystrophin-deficient mdx mouse has a milder phenotype than DMD patients in the context of cardiac and limb muscle. In contrast, the respiratory muscles, including the sternohyoid muscle, show severe mechanical weakness at a young age in the mdx mouse (Burns & O'Halloran, 2016) . Dystrophic diaphragm muscle undergoes repetitive cycles of degeneration and regeneration, with additional activation of inflammatory cascades that further exacerbate muscle weakness. Although diaphragm muscle function has been well characterized in DMD (De Bruin et al. 1997 ) and the mdx mouse (Coirault et al. 1999 (Coirault et al. , 2003 Bates et al. 2013) , little is known about the complementary muscles of breathing, especially the airway dilator muscles of the pharynx that are crucial in the control of airway calibre, which is surprising given the prevalence of sleep-disordered breathing in DMD boys (Bersanini et al. 2012) .
In the present study, we demonstrate that mdx sternohyoid muscle shows impaired performance at 8 weeks of age, consistent with our recent report (Burns & O'Halloran, 2016) . This functional impairment is characterized by reduced specific force (twitch and tetanic contractions), reduced maximal mechanical work and power production, and reduced V max . Work and power production as a function of load bearing was significantly A), interferon-γ induced protein (IP-10; B) and macrophage inflammatory protein 3α (MIP-3α; C) in sternohyoid muscle from WT (n = 7-8) and mdx (n = 7-8) mice injected S.C. with saline (0.9% w/v) or drug treatment [neutralizing interleukin-6 receptor antibodies (0.2 mg kg −1 ) and urocortin 2 (30 μg kg −1 ); co-administered] for 2 weeks. Data were statistically compared by two-way ANOVA followed by Bonferroni post hoc test. * * P < 0.01; * * * * P < 0.0001. Macrophage inflammatory protein 2: genotype, P < 0.0001; treatment, P < 0.0001; and interaction, P < 0.0001. Interferon-γ induced protein: genotype, P = 0.0002; treatment, P = 0.0007; and interaction, P = 0.0022. Macrophage inflammatory protein 3α: genotype, P = 0.0004; treatment, P = 0.0033; and interaction, P = 0.0510.
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reduced for mdx saline compared with WT saline. We observed a ß44% decrease in sternohyoid muscle peak tetanic force for mdx saline versus WT saline, which is consistent with previous findings (Attal et al. 2000; Burns & O'Halloran, 2016) . These studies reveal severe mechanical dysfunction in sternohyoid muscle from young and aged mdx mice, suggesting that upper airway obstruction in DMD might be a result of increased collapsibility of the pharyngeal airway arising from dysfunction of upper airway dilator muscles. Sternohyoid muscle weakness in mdx mice was associated with a shift in the MHC isoform distribution. Contractile performance in muscle is correlated with fibre-type distribution (Schiaffino & Reggiani, 2011) . The sternohyoid muscle is phasically active during respiration (Van de Graaff et al. 1984; O'Halloran et al. 2002) and is composed solely of fast fibres (type II). Type II fibres display progressively increasing force production from type IIa to IIx fibres, with type IIb fibres producing the greatest forces but least resistance to fatigue (Polla et al. 2004; Schiaffino & Reggiani, 2011) . We observed a significant decrease in the relative proportion of type IIb fibres with a concomitant increase in the type IIx fibre count in mdx muscle. Given that the type IIb fibres are the units producing the maximal force with the fastest kinetics, this finding is consistent with the functional data demonstrating decreased force-generating capacity and reduced shortening velocity in mdx compared with WT mice. Our findings are consistent with the observations of others (Attal et al. 2000) , who likewise reported reduced force-generating capacity and an increased proportion of type IIx and reduced type IIb fibres in sternohyoid muscle from aged (6-month-old) mdx mice. We reason that this shift in the fibre-type composition of the sternohyoid relates to muscle fibre degeneration and regeneration such that the muscle is in a relatively immature state. Muscle fibre remodelling will also alter motor neuronal input to the muscle. Given that muscle fibre types are determined by the motor unit that innervates them (Mantilla & Sieck, 2003) , it is plausible to speculate that dystrophic muscle might have an altered motor unit innervation pattern, which warrants investigation. There is a paucity of information pertaining to the accessory muscles of breathing in mdx mice. Unlike the well-characterized mdx diaphragm, the temporal profile of the mdx sternohyoid muscle structure-function relationship throughout life is unknown, but published works suggest that the sternohyoid most probably undergoes a similar pathology to mdx diaphragm muscle (Attal et al. 2000; Burns et al. 2016) .
The CSA of a muscle fibre is a determinant of force production. Cross-sectional area varies between fibres, increasing from type I fibres to type IIa and IIx, and type IIb (Fig. 3E) . In DMD, the cycles of degeneration and regeneration within muscles lead to alterations in fibre size. As such, dystrophic muscle has myofibres of varying size compared with the uniformity of diameter found in a normal muscle (Pastoret & Sebille, 1995) . Investigation of the CSA of individual muscle fibre types revealed that mdx sternohyoid shows evidence of hypertrophied type IIa and type IIx fibres. Increasing CSA can be viewed as an adaptive mechanism in the context of force production, often observed with resistance training that increases muscle strength. However, alterations in fibre size secondary to degeneration and regeneration are characteristic of mdx muscle, with regeneration producing hypertrophied fibres, which are often functionally weaker (Lynch et al. 2001) .
Dystrophic skeletal muscle undergoes progressive cycles of fibre degeneration and regeneration following damage, a process that continues until the regenerative capacity is exhausted. Skeletal muscle fibre central nucleation is a histological indicator of muscle fibre repair and regeneration. We observed a significant increase in the percentage of centrally nucleated myofibres in mdx sternohyoid compared with WT, with ß25% of mdx sternohyoid fibres presenting with central nuclei. This reveals that sternohyoid muscle from mdx mice is undergoing significant muscle damage and repair as early as 8 weeks of age, consistent with evidence of severe muscle weakness.
Inflammation is recognized to be a contributing factor to DMD pathology, which is characterized by a persistent inflammatory response in skeletal muscle because of chronic damage and stress to functional muscle fibres owing to the absence of dystrophin (Deconinck & Dan, 2007) . Inflammatory cell infiltration of damaged and degenerating dystrophic muscle fibres is a hallmark feature of skeletal muscle pathology in DMD. Inflammatory cell infiltration has been shown to exacerbate myofibre damage in mdx mice (Evans et al. 2009a) , with loss of muscle fibres, subsequent fibrosis and adipose tissue deposition, culminating in impaired muscle function (Deconinck & Dan, 2007) . We observed a significant increase in putative inflammatory cell infiltration in young mdx sternohyoid muscle, typically thought to be associated with muscle damage and subsequent regeneration. Enhanced inflammatory cell infiltrate drives a fibrotic environment (Pelosi et al. 2015b) . Indeed, we observed a significant increase in the collagen content of the mdx sternohyoid. Fibrosis is well characterized in the diaphragm of mdx mice (Stedman et al. 1991) , but to our knowledge this is the first report of enhanced collagen deposition in a complementary muscle of breathing, the sternohyoid. Enhanced collagen deposition within the muscle impairs muscle functional performance, which given the role of the sternohyoid as an airway dilator has implications for adequate control of airway calibre in DMD.
Duchenne muscular dystrophy patients and the mdx mouse have elevated levels of circulating Factors contributing to pharyngeal dilator weakness in mdx mice pro-inflammatory cytokines, namely IL-1, IL-6 and tumour necrosis factor-α (Gosselin & Williams, 2006) , promoting an inflammatory response associated with dystrophic changes (Kumar & Boriek, 2003) . Anti-inflammatory treatment with glucocorticoids is the main treatment strategy in delaying loss of ambulation in DMD, but treatment is unfortunately associated with deleterious side-effects (Pichavant et al. 2011) . Therefore, there is a need for new therapeutic strategies that can rescue or at least halt muscle impairments in DMD.
Interleukin-6 is a pleiotropic cytokine, exhibiting both pro-and anti-inflammatory properties, hence mediating diverse biological functions (Pedersen & Febbraio, 2008) . Several studies have targeted pro-inflammatory cytokine signalling in mdx mice and examined their respective roles in the dystrophic process. Inhibition of tumour necrosis factor-α has been shown to have beneficial effects in mdx mice (Messina et al. 2006 (Messina et al. , 2009 ). Interleukin-6 has been shown to promote muscle atrophy in rats (Haddad et al. 2005 ) and mice (Tsujinaka et al. 1996) , which is amenable to blockade. Additionally, mdx mice crossed with mice overexpressing IL-6 present with a significant reduction in limb muscle force and a decline in performance during treadmill exercise, indicative of impaired muscle function (Pelosi et al. 2015b) . Treatment with an xIL-6R antibody, blocking IL-6 signalling, has been shown to decrease pro-inflammatory cytokine expression in the diaphragm, improving treadmill performance in mdx mice (Pelosi et al. 2015b) .
In the present study, co-administration of an IL-6 neutralizing antibody (xIL-6R) and a CRFR2 agonist (Ucn2) in mdx mice resulted in significantly increased force-generating capacity compared with mdx mice treated with saline (ß86% increase). Specific force in mdx sternohyoid after treatment was increased to values equivalent to WT saline. Drug treatment increased mdx sternohyoid work, power and shortening velocity throughout the load continuum (0-60% max tension). Increased work production after treatment in mdx is attributable to a positive inotropic effect on force-generating capacity, because we observed no significant difference in peak shortening between the mdx treatment and mdx saline groups. In contrast, increased mdx sternohyoid power production is attributable to an increase in both force-generating capacity and shortening velocity. Drug treatment in WT mice also had a positive inotropic effect on force generation (ß49% increase) compared with the WT saline group. For WT, drug treatment increased sternohyoid work and power as a function of load bearing, both of which are attributable to an inotropic effect on muscle force. Significant increases in WT sternohyoid specific force suggest direct inotropic effects of drug co-treatment on sternohyoid muscle fibres. However, it should be noted that we determined tissue, and not fibre, CSA for our calculation of specific force. Therefore, whilst our measurement accounts for force normalized to tissue CSA, it does not account for alterations in myofibre CSA, which contribute to force generation in muscle. This is an important distinction because drug co-treatment caused fibre hypertrophy in WT (but not mdx) muscle. Urocortin 2 elevates cAMP, protein kinase A and the cAMP-binding protein, Epac (Reutenauer-Patte et al. 2012) , and improves calcium homeostasis in calcium overloaded mdx striated muscle with beneficial protective effects, reducing muscle necrosis (Reutenauer-Patte et al. 2012) . The CRFR2 agonists increase muscle fibre mass, with evidence of increased muscle fibre CSA and absolute muscle force (Hinkle et al. 2004) , in addition to actions that prevent atrophying of muscle in various experimental models (Hinkle et al. 2003 (Hinkle et al. , 2004 . As such, we posit that fibre hypertrophy probably contributed to enhanced force generation in WT sternohyoid. It remains unclear, however, whether drug co-treatment exerted direct inotropic effects on myofibres contributing to muscle force. Of interest, direct positive inotropic effects of Ucn2 have been noted in the treatment of heart failure (Bale et al. 2004) , and Ucn2 has been shown to exert a positive inotropic effect in the isolated rat heart through mechanisms dependent on cAMP (Calderon-Sanchez et al. 2009 ), a major regulator of skeletal muscle contractility (Berdeaux & Stewart, 2012) .
Drug treatment in mdx mice significantly reduced type IIx and increased type IIb fibre distribution compared with the untreated mdx saline group. As such, drug treatment restored or prevented fibre-type transitions that are evident in the mdx saline group compared with WT saline. The preservation of type IIb fibres is likely to contribute to the restoration of muscle force in mdx sternohyoid. Conversely, there was no difference in the distribution of any fibre type in the WT drug treatment group compared with WT saline. Urocortin 2 has been shown to induce anabolism in skeletal muscle (Reutenauer-Patte et al. 2012) . Anabolism in fibres supports increased force production, which could be beneficial to the dystrophic muscles of mdx mice. Interestingly, we observed hypertrophy of type IIb fibres in WT sternohyoid, but not mdx sternohyoid, after drug treatment, revealing a different structural basis for improved force comparing WT (hypertrophy) with mdx (fibre preservation).
Drug treatment in mdx mice slightly ameliorated sternohyoid muscle fibre central nucleation compared with the mdx saline group; conversely, the percentage of central nucleation was unaffected by treatment in WT sternohyoid. This suggests that drug treatment suppressed muscle fibre damage, resulting in fewer necrotic fibres, which should be beneficial for muscle performance. This observation highlights that muscle fibre preservation (and maturation to type IIb) is likely to be an important contributor to force generation in mdx treated muscles D. P. Burns and others in our study. However, of interest, drug treatment had no effect on collagen content or putative immune cell infiltration in mdx sternohyoid. As such, drug treatment was ineffective in reducing muscle fibrosis, perhaps resulting from muscle inflammation. As we did not characterize the nature of the infiltrate area (which we concede will also include non-immune cell types), we are unable to determine whether drug treatment altered the cellular milieu in the interstitial spaces between myofibres. Chemokines were significantly increased in mdx sternohyoid muscle, which is consistent with previous reports of elevated chemokines in muscle from mdx mice (Porter et al. 2003; Demoule et al. 2005) . Interestingly, drug treatment in mdx mice significantly increased the content of chemo-attractant agents, suggesting that there might be a heightened immune response in mdx muscle after drug treatment. Such a response could act to recruit immune cells to repair damaged muscle fibres, and thus, lead to functional improvements in sternohyoid muscle, perhaps contributing to the impressive force recovery observed in our study.
From the present work, we cannot ascertain which of the two drug treatments is responsible for the inotropic and structural effects observed in WT and mdx mice. Recent work investigated the individual roles of xIL-6R and Ucn2 in improving mdx diaphragm force (Manning et al. 2017) . Of relevance to the present study, Manning et al. (2017) revealed an additive effect of xIL-6R and Ucn2 co-treatment on diaphragm muscle force, providing the rationale for our combined drug approach. Additional studies describing the cellular mechanisms whereby xIL-6R and Ucn2 improve sternohyoid muscle function are warranted.
Our relatively short (2 week) intervention has yielded impressive findings, preserving sternohyoid muscle force-generating capacity in mdx mice. Although there are no temporal studies of the mdx sternohyoid during development to adulthood, the drug treatment began at a time when significant muscle remodelling is likely to be under way (based on work in mdx diaphragm (Coirault et al. 2003 ). Intervention at a younger age and for a longer treatment duration would be an interesting study to explore the efficacy of the drug treatment before onset of muscle necrosis. It would also be of interest to determine whether performance is preserved in older animals after treatment and if there are any adverse side-effects attributable to prolonged drug treatment. Although drug treatment fully restored sternohyoid muscle force, there was no difference in the relative area of infiltration in the mdx sternohyoid drug treatment group compared with the mdx saline group. Our data suggest that the beneficial effect of drug treatment on sternohyoid muscle fibre form and function is achieved without any apparent influence on local muscle inflammation and fibrosis, linked to on-going muscle fibre damage and repair. This suggests that the beneficial effect of the drug therapy relates to a retardation in muscle fibre damage, allowing maturation of functional fibres, but without overt changes in muscle infiltrate. However, it is important to note that the nature of the inflammatory infiltrate might be favourably altered by drug treatment. Macrophages can exist in one of two states, M1 or M2. Although M2 macrophages contribute to muscle repair, M1 macrophages can increase muscle fibre lysis (Villalta et al. 2015) . Therefore, depending on the state of the infiltrating macrophage, inflammation can result in adaptive or maladaptive processes, promoting regeneration or driving muscle wasting. We did not characterize the nature of the infiltrate in mdx mice, and therefore, we cannot comment on the effect of drug treatment on the immune cell signature in mdx muscle. This requires further investigation, especially in the light of our observation that chemokines were increased in mdx muscle and further increased by drug treatment, which may have established a beneficial immune response that favoured muscle performance. We also acknowledge that IL-6 blockade may have arrested beneficial actions of the myokine in muscle, such as promoting myoblast proliferation and myotube formation.
In summary, mdx sternohyoid shows evidence of severe mechanical dysfunction and fibre-type immaturity at an early age. Co-treatment with an anti-IL-6 receptor antibody and CRF2 receptor agonist (Ucn2) had a positive inotropic effect, restoring mechanical force and power in dystrophic sternohyoid muscle. Drug treatment preserved fibre complement in mdx sternohyoid and slightly ameliorated the proportion of fibres with evidence of central nucleation, indicative of damage. Preservation of MHC type IIb fibres and a partial reduction in centronucleation, suggesting a preservation of functional fibres, might underpin, at least in part, the recovery of force production in the mdx drug-treated mice. After a relatively short drug intervention period, recovery of contractile function was impressive in our study, highlighting the potential utility of this combination therapy in DMD.
